# US 2022/0031777 A1 · Methods of Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031777 A1
- Document ID: US20220031777A1
- Status: Published application
- Kind: A1
- Application number: 17/367,788
- Filed: 2021-07-06
- Published: 2022-02-03
- Earliest claimed: 2019-01-07
- Assignees: KaliVir Immunotherapeutics, Inc.
- Applicants: KaliVir Immunotherapeutics, Inc.
- Inventors: Stephen H. THORNE
- Web page: https://patentgrep.com/patent/US20220031777A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- C12N 1/20: Bacteria; Culture media therefor
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/763: Herpes virus
- A61K 35/766: Rhabdovirus, e.g. vesicular stomatitis virus
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/24132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/20232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.

## Claims

### Claim 1

A method of treating a tumor in a subject, comprising:
administering to the subject a first recombinant microorganism,
wherein the first recombinant microorganism replicates in a tumor cell and does not replicate in a non-tumor cell or displays attenuated replication in a non-tumor cell, and
wherein the first recombinant microorganism is a virus or a bacterium;
administering to the subject a second recombinant microorganism,
wherein the second recombinant microorganism replicates in a tumor cell and does not replicate in a non-tumor cell or displays attenuated replication in a non-tumor cell, and
wherein the second recombinant microorganism is a virus; and
enhancing or eliciting an immune response to a protein expressed by a tumor associated cell that is not coded for or expressed by the first recombinant microorganism and the second recombinant microorganism.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immune response is demonstrated by one or more of a decrease in the volume of the tumor in the subject, a decrease in the level of expression of one or more tumor proteins in the subject or a sample from the subject, a decrease in the number of tumor sites in the subject, a change in viral load in the subject or the sample from the subject, a change in population of immune cells in the subject or the sample from the subject, a change in expression levels of an immune cell marker in the subject or the sample from the subject, an enhancement of B-cell proliferation in the subject or the sample from the subject, an enhancement of CD4+ T cell proliferation in the subject or the sample from the subject, an enhancement of CD8+ T cells proliferation in the subject or the sample from the subject, an enhancement of cytokine production in the subject or the sample from the subject, an enhancement of antigen presenting cell proliferation in the subject or the sample from the subject, or any combinations thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the immune response is demonstrated by the decrease in the level of expression of one or more tumor proteins, the change in population of immune cells, the change in expression levels of an immune cell marker, the enhancement of B-cell proliferation, the enhancement of CD4+ T cell proliferation, the enhancement of CD8+ T cells proliferation, the enhancement of cytokine production, the enhancement of antigen presenting cell proliferation, or any combinations thereof, in the subject or the sample from the subject, wherein the sample from the subject is a blood, tissue, urine, or saliva sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immune response can be detected at a time point at or after the administration of the first or second recombinant microorganism.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first recombinant microorganism does not replicate in the non-tumor cell.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first recombinant microorganism displays attenuated replication in the non-tumor cell.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the second recombinant microorganism does not replicate in the non-tumor cell.

### Claim 10 (depends on 1)

The method of claim 1, wherein the second recombinant microorganism displays attenuated replication in the non-tumor cell.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the first recombinant microorganism is a bacterium.

### Claim 16 (depends on 15)

The method of claim 15, wherein the first recombinant microorganism is an enterobacterium, a listeriaceae bacterium, or a streptococcaceae bacterium.

### Claim at position 17

17-33. (canceled)

### Claim 34 (depends on 1)

The method of any one of claim 1, wherein the first recombinant microorganism is a virus.

### Claim 35 (depends on 15)

The method of claim 15, wherein the first recombinant microorganism is of family viridae.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the first recombinant microorganism comprises a poxvirus, a picornavirus, an adenovirus, a parvovirus, a herpesvirus, a reovirus, a paramyxovirus, a rhabdovirus, an orthomyxovirus, or a coxsackievirus.

### Claim at position 23

39-100. (canceled)

### Claim 101 (depends on 1)

The method of claim 1, wherein the second recombinant microorganism is of family viridae.

### Claim 102

(canceled)

### Claim 103

(canceled)

### Claim 104 (depends on 101)

The method of claim 101, wherein the second recombinant microorganism is a poxvirus, a picornavirus, an adenovirus, a parvovirus, a herpesvirus, a reovirus, a paramyxovirus, a rhabdovirus, an orthomyxovirus, or a coxsackievirus.

### Claim at position 28

105-153. (canceled)

### Claim 154 (depends on 1)

The method of claim 1, wherein the first recombinant microorganism and the second recombinant microorganism are administered to the subject simultaneously.

### Claim 155 (depends on 154)

The method of claim 154, wherein the first recombinant microorganism is formulated in a delayed release composition, a sustained release composition, an immediate release composition, a stealth release composition, or any combinations thereof.

### Claim 156

(canceled)

### Claim 157 (depends on 1)

The method of claim 1, wherein the second recombinant microorganism is administered to the subject after the first recombinant microorganism is administered to the subject.

### Claim 158 (depends on 157)

The method of claim 157, wherein the second recombinant microorganism is administered from about 1-60 days, from 1-45 days, from 1-30 days, from 1-15 days, from 1-10 days, or from 1-7 days after administration of the first recombinant microorganism.

### Claim 159 (depends on 157)

The method of claim 157, wherein the second recombinant microorganism is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 21, 28, 35, 56, or 60 days after administration of the first recombinant microorganism.

### Claim 160 (depends on 157)

The method of claim 157, wherein the second recombinant microorganism is administered to the subject one, two, three, three, four, five or more times.

### Claim 161 (depends on 157)

The method of claim 157, wherein the second recombinant microorganism is administered to the subject two, three, three, four, five or more times with about 1-60 days, 1-45 days, 1-30 days, 1-15 days, 1-10 days, 1-7, 1-5 days, or 1-3 days between each administration.

### Claim at position 37

162-166. (canceled)

### Claim 167 (depends on 1)

The method of claim 1, wherein the first recombinant microorganism is administered intra-tumorally, intradermally, subcutaneously, intraperitoneally, intramuscularly or intravenously; and the second recombinant microorganism is administered intra-tumorally, intradermally, subcutaneously, intraperitoneally, intrathecally, intramuscularly or intravenously.

### Claim 168

(canceled)

### Claim 169 (depends on 1)

The method of claim 1, further comprising administering an anti-cancer therapy.

### Claim at position 41

170-183. (canceled)

### Claim 184

A method of treatment, comprising:
administering to a subject a first recombinant microorganism,
wherein the first recombinant microorganism comprises an exogenous nucleic acid encoding a cytokine receptor,
wherein the first recombinant microorganism replicates in a tumor microenvironment, and
wherein the first recombinant microorganism is a virus or a bacterium;
administering to the subject a second recombinant microorganism,
wherein the second recombinant microorganism comprises an exogenous nucleic acid encoding a cytokine receptor,
wherein the second recombinant microorganism replicates in a tumor microenvironment, and
wherein the second recombinant microorganism is an oncolytic virus; and
enhancing or eliciting an immune response to a protein expressed by a non-tumorous cell present within the tumor microenvironment that is not coded for or expressed by the first recombinant microorganism and the second recombinant microorganism.
